Take advantage of the world’s fastest-growing clinical trials region to accelerate your global clinical development by leveraging Novotech’s global footprint, relationships, and infrastructure.

Delve into the details of this full-service global product development and strategic regulatory group that has a proven track record of successful FDA meetings and approvals.

Get streamlined and integrated clinical trial services delivered by a dedicated team of professionals with deep industry and therapeutic area expertise across all phases of clinical development. 

Start getting accurate, high-quality, and timely biostatistics services delivered by this team of biostatisticians and statistical programmers, in addition to statistical planning, analysis, and reporting.

Novotech relies on years of experience, in-country knowledge, and real-life big data to identify and propose the best-performing sites. Uncover the possibilities for your next study.

Biotechnology companies are facing increased challenges around participant recruitment and retention, lengthy timeframes, and relatively high costs.

Our talented and experienced team can assist in all Clinical Study Phases (Phase 0, I, II and III) and in study designs ranging from First in Human (FIH), Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Drug-Drug Interaction (DDI), Bioavailability/Bioequivalence (BA/BE), Food Effect as well as Special Population studies.

Novotech initiated the first national, privately owned, commercial Institutional Biosafety Committee (IBC) in Australia, successfully accredited by the Australian Office of the Gene Technology Regulator (OGTR).

Biotechnology companies consider locations in the Asia-Pacific region, such as South Korea and China to access vast treatment-naïve patient populations and accelerate their clinical trials at lower costs.

Many biotechnology companies look at the Asia-Pacific region for their trials in Infectious diseases and Vaccines due to the high prevalence of diseases such as Hepatitis (Hepatitis B, Hepatitis C), HIV, and Influenza across the region.

There may be as many as 8,000 rare diseases, affecting between 6% and 8% of the worldwide population in total. It is estimated there are about 30 million affected people in the EU and in North America, while over 45 million people may be suffering from a rare condition in Asia, with 10 million people in China alone.

Hear from a panel of industry experts on dissecting the shift in early-phase oncology design, focusing on Bayesian Data.

Hear from a panel of life science experts about the most recent developments and ground-breaking approaches shaping the field of vaccine development worldwide.

The webinar features regulatory affairs and investment leaders from North America and Asia Pacific who will discuss why biotech companies are increasingly exploring clinical opportunities in Asia Pacific to generate diverse, globally accepted clinical trial data, and much more.

In this webinar, gain insight into the latest regulatory and clinical developments in the field of oncology in China.

This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers.

Discover how the clinical research bridge between China and the US supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications.

China now represents 60% of clinical development in CAR-T therapy development globally: what have we learned to date and where are future opportunities?

Uncover why the collaboration between researchers, clinicians, regulatory bodies, and CROs remains crucial for innovative solutions and improved patient outcomes in the journey to address metastatic breast cancer challenges.

While APAC is at the forefront of dyslipidaemia research, gain insight into pharmaceutical companies' continued new treatment developments and innovative therapies.

Unearth how targeted medicines and immunotherapy have emerged as viable treatment options, offering hope for improved outcomes and quality of life for NSCLC patients.

Explore the clinical landscape of hemophilia across three key regions of the globe namely Asia Pacific, Europe, and North America.

See how the development of new drug classes offers the potential for better PBC management, addressing its global impact.

While numerous opportunities are available for companies seeking to undertake CAR-T research in China, understand why embarking on this path requires careful consideration.

Explore the exciting advancements in CNG treatment, such as innovative therapies, ongoing clinical trials, and their potential to positively influence patient outcomes.

With ongoing technological advancements, consider several factors as to why experts believe that Virtual Clinical Trials will continue to play a significant role even beyond the post-pandemic era, despite its unique set of challenges.

Delve into the swiftly evolving trends that are reshaping the clinical trial industry and examine potential implications for introducing innovative solutions to the market.

Contract research organizations can be invaluable partners in clinical trials. Dive into the full spectrum of benefits you'll experience by partnering with a globally established and well-resourced CRO.

Discover the advantages of incorporating Europe and APAC regions in clinical trial endeavors, such as accelerated recruitment, streamlined regulatory procedures, access to diverse patient populations, and ultimately, significant cost reductions.

Learn about ADCs advancements in cancer treatment and how the therapy could potentially revolutionize the field by reducing the often severe side effects associated with traditional chemotherapy.

Consider the advantages associated with conducting early- to late-phase clinical trials in China and the broader APAC region, as well as potential challenges that could impact the trial process and patient outcomes

Gain insight into how teams can create clinical pathways and develop trial designs made for success.

Get a full overview of the role CROs play in clinical trials and their impact on site selection, site monitoring, patient recruitment, managing data, and more.

Get an overview of the exciting advancements in gallbladder cancer (GBC) treatment, emphasizing pioneering medications, ongoing clinical trials, and their potential to revolutionize patient outcomes.

Explore exciting advancements in the treatment of nasopharyngeal carcinoma (NPC), specifically pharmaceuticals, ongoing clinical trials, and their potential to significantly improve patient prognosis and outcomes.

Dive into the global clinical trial landscape of Crohn's disease (CD), its trends in the Asia Pacific, and what the industry is doing to look for a cure.

Gain a better understanding of the global clinical trial landscape of Non-Hodgkin lymphoma (NHL) and its trends in the Asia Pacific.

Unearth how health officials are preparing to meet the rising demand for resources regarding liver cancer and ensure effective management throughout the cancer pathway.

Get a full overview of the current clinical trial landscape as it relates to HNC and where treatment efforts are headed in the future.

Uncover how pipeline drugs, especially small molecules, offer the potential to transform gallbladder cancer management, ultimately improving patient outcomes and addressing its global impact.

Read this report to better understand why a collaborative, multidisciplinary approach is essential to address NPC's complexities and achieve groundbreaking progress in its management.

Traversing the so-called “valley of death” and forging a successful pathway to clinical development hinges on determining the optimal strategy for a product and indication.

Gain valuable insights into the current state of cell and gene therapy clinical trials and the opportunities and challenges in this rapidly evolving field.

Discover how a well-designed and robust preclinical development plan can help identify potential safety and efficacy issues early in the drug development process, ultimately reducing the risk of failure in clinical trials.

Learn about the incidence, distribution, and possible control of idiopathic pulmonary fibrosis (IPF) in the Asia Pacific region, in addition to the standard of care, current trial landscape, and more.

Gain a better understanding of the incidence, distribution, and possible control of Alzheimer’s disease (AD) in the Asia Pacific region, the standard of care, the trial landscape, and more.

Gain a better understanding of the incidence, distribution, and possible control of rheumatoid arthritis (RA) in the Asia Pacific region, the standard of care, the trial landscape, and more.

Gain a better understanding of the incidence, distribution, and possible control of acute myeloid leukemia (AML) in the Asia Pacific region, the standard of care, the trial landscape, and more.

Better understand the incidence, distribution, and possible control of prostate cancer (PCa) in the Asia Pacific region, the standard of care, the trial landscape, and more.

Better understand the incidence, distribution, and possible control of breast cancer in the Asia Pacific region, the standard of care, the trial landscape, and more.

Better understand the incidence, distribution, and possible control of melanoma in the Asia Pacific region, the standard of care, the trial landscape, and more.

Better understand the incidence, distribution, and possible control of ovarian cancer (OC) in the Asia Pacific region, the standard of care, the trial landscape, and more.

China is leading the world in oncology and CAR-T research. And with over a billion people and a government friendly to biotech, it’s an ideal location for international clinical trials.

Global clinical trials in the Asia-Pacific region are becoming an attractive solution for young biotech companies looking to utilize their capital efficiently and secure high-quality clinical data quickly.

Opting to take your biotech program global can help save crucial resources, produce high-quality clinical data for your therapy, and leverage unique regional advantages like region-specific indication strategies.

In the coming years, the global burden of Parkinson's Disease (PD) is expected to rise. The number of people with PD in Asia is anticipated to exceed 6 million by 2030. Discover the factors leading to this in this report.

In December 2019, a novel coronavirus was discovered in China causing severe acute respiratory syndrome-like pneumonia which resulted in a pandemic. Find out more details regarding its spread in this report.

Read more about how the large population and lower volume of studies decreases competing trial risk in this region with a great need for novel drug therapies for solid tumors in Asian patients

Psoriasis can have a significant psychological effect on both the patient and their family. Explore the cultural factors, socioeconomic factors, and higher levels of social stigma and prejudice resulting that make this disease more prevalent in Asia.

DLBCL is the most prevalent Non-Hodgkin Lymphoma (NHL) which accounts for about 30%-40% of all NHL cases worldwide. Explore its prevalence in the Asia Pacific region in this report.

Clostridium difficile infection is one of the leading causes of morbidity and mortality worldwide. Find out more about this disease in Asia, where a mean overall prevalence of nearly 15.0% was found among hospital patients.

Even though NAFLD (non-alcoholic fatty liver disease) is a significant public health burden in the United States and Europe, learn why Asia has a NAFLD burden that is increasing faster than the developed countries of the West.

Find out how the incidence and prevalence of Ulcerative Colitis in Asia has rapidly increased over the past four decades with an incidence rate of around 6 cases per 100,000 population.